In ECC and GBC of our cohort, ERBB2 alterations occurred in up to 2.6%–8.5% of cases, whereas its prevalence in ICC is much lower (1.4%), consistent with corresponding data reported in the Western cohort (63, 64). The gene discussed is ERBB2; the disease is intrahepatic cholangiocarcinoma.